AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 282 min read$DBVT

DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update

DBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Press Release Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update • Submitted the Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in children aged 4-7 Years and requested Prior

Original reporting
SEC EDGAR 8-K
Published Oct 28, 2026, 9:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DBVT
Bullish
medium confidence
Mentioned
$DBVT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DBVTBullishLow
01

Why it matters

The 8‑K provides the first public disclosure of the BLA submission and cash runway, which could influence short‑term trading sentiment.

02

Market read

The filing is a primary source of new company‑specific data; impact is confined to DBVT and its niche sector.

03

What to watch

Potential delays in the toddler BLA and reliance on contract manufacturer Fareva could pose execution risk.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

DBVT is a late‑stage specialty biopharma developing a peanut allergy patch. The company recently received an FDA warning to its contract manufacturer and is now submitting BLAs for two age groups.

Company-level read

Ticker impact

$DBVTBullishMedium confidence
Context

DBVT filed an 8‑K reporting Q3 2026 results, cash balance of $165.7 M and submission of a BLA for its VIASKIN® Peanut Patch.

Expected impact

potential upward pressure as investors price in the BLA submission and strong cash position

Evidence & confidence

New cash balance and regulatory progress are material for a clinical‑stage biotech; no guidance change is disclosed, so impact is limited.

Market effects

Sector

Adds positive momentum to the allergy‑immunotherapy biotech niche.

Regional

Limited to US and European investors tracking specialty biopharma.

Global

Minimal; the news is company‑specific.

Counterpoint

What could challenge this read

The BLA may face further FDA scrutiny, and cash burn remains high, limiting upside.

Key entities

  • Contract Manufacturer
    Fareva

    DBVT's manufacturing partner addressing FDA warning.

  • Investor
    RA Capital Management

    Purchased $50 M of ADSs in the refreshed ATM program.

Read at source← All news

Related articles

SEP 30
$DBVTMedAI 8/10

DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young Children

DBV Technologies (DBVT) submitted a Biologics License Application to the FDA for its VIASKIN Peanut Patch in children aged 4-7, seeking Priority Review. The patch uses epicutaneous immunotherapy to desensitize children to peanut allergens. The submission follows positive Phase 3 trial results, meeting primary endpoints. DBVT stock closed at $11.55, up to $11.76 in overnight trading.

rttnews.com2 min
SEP 30
$DBVTMedAI 8/10

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

DBV Technologies S.A. (DBVT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years • The BLA is supported by the results from the successful Phase 3 VITESSE trial – the largest immunotherapy clinical trial to

SEC EDGAR 8-K2 min
SEP 29
$DBVTMedAI 8/10

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

DBV Technologies submitted a Biologics License Application to the FDA for its VIASKIN® Peanut Patch for children aged 4-7. The application is supported by positive Phase 3 trial results and seeks Priority Review. The patch uses epicutaneous immunotherapy to treat peanut allergies. DBV's shares trade on Euronext Paris and Nasdaq.

globenewswire.com2 min
JUL 30
$DBVTMedAI 8/10

DBV Technologies S.A.: DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq

Châtillon, France, July 30, 2026 DBV Technologies Announces Sale of Approximately $50 Million of ADSs Through Its At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Capital Market: DBVT) (the "Company"), a late-stage biopharmaceutical company, today announced that, pursuant to the Company's At-The-Market Program established on September 1, 2025 and included in a new registration statement and accompanying prospectus filed on July 27, 2026, (the...

finanznachrichten.de4 min